Joint WFH-ISTH session: issues in clinical trial design

Area of Science:

• Hematology
• Pharmacology
• Regulatory Science

Background:

• The field of haemophilia therapy is rapidly evolving with numerous novel clotting factor concentrates.
• Regulatory approval hinges on rigorous safety and efficacy assessments.

Purpose of the Study:

• To review the challenges in clinical trials and regulatory approval for new haemophilia treatments.
• To discuss the role of international organizations in addressing these challenges.

Main Methods:

• Review of regulatory requirements for clotting factor concentrates.
• Analysis of challenges in preauthorization clinical trials, including patient recruitment and antibody development.
• Examination of post-authorization safety data collection (Phase IV).

Main Results:

• Low prevalence of haemophilia complicates clinical trial recruitment.
• Inhibitory antibodies are a major adverse event, posing challenges for safety assessment.
• Lack of regulatory harmonization and difficulties in obtaining quality Phase IV data are significant hurdles.

Conclusions:

• Addressing challenges in clinical trials and regulatory harmonization is essential for advancing haemophilia therapy.
• The World Federation of Hemophilia and International Society on Thrombosis and Haemostasis play key roles in facilitating discussions and promoting standards.